annb0t
Top 20
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection.
With Illuccix now available for delivery to all positron emission tomography (PET) imaging sites in Australia, Austin Health in Melbourne became the first to administer this...
>>> Read more: First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
With Illuccix now available for delivery to all positron emission tomography (PET) imaging sites in Australia, Austin Health in Melbourne became the first to administer this...
>>> Read more: First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
